{"schema_version":"1.0","type":"article","title":"體內 CAR-T 的泡沫，還是下一代細胞治療最貴的門票？","url":"https://drugnews.com.tw/articles/2026-05-03-in-vivo-cart-kelonia-lilly.html","markdown_url":"https://drugnews.com.tw/articles/2026-05-03-in-vivo-cart-kelonia-lilly.md","lang":"zh-Hant","date":"2026-05-03","publish_at":"2026-05-03T10:30:00+08:00","updated_at":"2026-05-03","category":"商業分析系列","topic":"商業分析系列","tags":["Dcard","免費文章","CAR-T","Kelonia","J&J","Gilead","生技投資"],"summary":"📌 4 月 20 日，Eli Lilly 宣布將以最高 70 億美元收購臨床階段生技公司 Kelonia Therapeutics，其中包含 32.5 億美元現金預付款，其餘則取決於後續臨床、監管與商","key_points":[],"facts":[],"sections":["01｜為什麼估值愈來愈貴？","02｜Lilly 其實不是在買兩家公司，而是在買兩種完全不同的細胞治療哲學","03｜這不是 Lilly 一家的熱情，而是大藥廠集體提前卡位","04｜但樂觀之外，風險也正在被快速放大","05｜所以，這是泡沫嗎？"],"references":[{"title":"[0]:各公司官網＆公開資料","source":"","date":"","url":""},{"title":"[1]:","source":"","date":"","url":""},{"title":"[2]:","source":"","date":"","url":""},{"title":"Kelonia Therapeutics Presents First-in-Human Data from Phase 1 inMMyCAR Study of KLN-1010 in vivo BCMA CAR-T Therapy at the American Society of Hematology (ASH) 2025 Annual Meeting   - Kelonia","source":"","date":"","url":""},{"title":"100% MRD-negative response rate in four patients; all remain in response through the longest follow up of 5 months  Favorable toxicity profile with no CRS grade 3 or above and no ICANS  Potent CAR-T expansion from a single, an off-the-shelf infusion witho","source":"","date":"","url":""},{"title":"keloniatx.com","source":"","date":"","url":""},{"title":"[3]:","source":"","date":"","url":""},{"title":"www.astrazeneca.com","source":"","date":"","url":""},{"title":"https://www.astrazeneca.com/media-centre/press-releases/2025/astrazeneca-to-acquire-esobiotec.html","source":"","date":"","url":"https://www.astrazeneca.com/media-centre/press-releases/2025/astrazeneca-to-acquire-esobiotec.html"},{"title":"www.astrazeneca.com","source":"","date":"","url":""},{"title":"[4]:","source":"","date":"","url":""},{"title":"[5]:","source":"","date":"","url":""},{"title":"Science","source":"kelonia","date":"","url":""},{"title":"Unlocking the full promise of genetic medicine while expanding the benefits & reach of these genetic therapies to help all patients.","source":"","date":"","url":""},{"title":"keloniatx.com","source":"","date":"","url":""},{"title":"[6]:","source":"","date":"","url":""},{"title":"reuters.com","source":"","date":"","url":""},{"title":"https://www.reuters.com/legal/litigation/gilead-unit-acquire-cell-therapy-developer-interius-350-million-2025-08-21/","source":"","date":"","url":"https://www.reuters.com/legal/litigation/gilead-unit-acquire-cell-therapy-developer-interius-350-million-2025-08-21/"},{"title":"www.reuters.com","source":"","date":"","url":""},{"title":"[7]:","source":"","date":"","url":""},{"title":"AbbVie and Umoja Biopharma Announce Strategic Collaboration to Develop Novel In-Situ CAR-T Cell Therapies - Jan 4, 2024","source":"","date":"","url":""},{"title":"Collaboration to leverage Umoja's VivoVecTM gene delivery platform and AbbVie's expertise in oncology to develop in-situ generated chimeric antigen receptor (CAR)-T cell therapy candidates NORTH...","source":"","date":"","url":""},{"title":"news.abbvie.com","source":"","date":"","url":""},{"title":"[8]:","source":"","date":"","url":""},{"title":"In vivo generation of anti-BCMA CAR-T cells in relapsed or refractory multiple myeloma: a phase 1 study","source":"","date":"","url":""},{"title":"In vivo chimeric antigen receptor (CAR)-T cell generation can bypass ex vivo manufacturing and lymphodepletion, potentially simplifying and accelerating access to cellular therapy; preliminary clinical experience supports feasibility and suggests prelimin","source":"","date":"","url":""},{"title":"pubmed.ncbi.nlm.nih.gov","source":"","date":"","url":""},{"title":"[9]:","source":"","date":"","url":""},{"title":"www.biospace.com","source":"","date":"","url":""},{"title":"https://www.biospace.com/press-releases/magicrnas-first-in-human-clinical-data-demonstrating-feasibility-of-in-vivo-car-t-therapy-in-systemic-lupus-erythematosus-published-in-the-new-england-journal-of-medicine","source":"","date":"","url":"https://www.biospace.com/press-releases/magicrnas-first-in-human-clinical-data-demonstrating-feasibility-of-in-vivo-car-t-therapy-in-systemic-lupus-erythematosus-published-in-the-new-england-journal-of-medicine"},{"title":"www.biospace.com","source":"","date":"","url":""}],"images":[{"alt":"Dcard 原圖：體內 CAR-T 的泡沫，還是下一代細胞治療最貴的門票？","url":"https://drugnews.com.tw/assets/articles/in-vivo-cart-kelonia-lilly/dcard-01.webp"},{"alt":"Dcard 原圖：體內 CAR-T 的泡沫，還是下一代細胞治療最貴的門票？","url":"https://drugnews.com.tw/assets/articles/in-vivo-cart-kelonia-lilly/dcard-02.webp"},{"alt":"Dcard 原圖：體內 CAR-T 的泡沫，還是下一代細胞治療最貴的門票？","url":"https://drugnews.com.tw/assets/articles/in-vivo-cart-kelonia-lilly/dcard-03.png"},{"alt":"Dcard 原圖：體內 CAR-T 的泡沫，還是下一代細胞治療最貴的門票？","url":"https://drugnews.com.tw/assets/articles/in-vivo-cart-kelonia-lilly/dcard-04.png"},{"alt":"Dcard 原圖：體內 CAR-T 的泡沫，還是下一代細胞治療最貴的門票？","url":"https://drugnews.com.tw/assets/articles/in-vivo-cart-kelonia-lilly/dcard-05.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/in-vivo-cart-kelonia-lilly/dcard-01.webp","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-05-03）。體內 CAR-T 的泡沫，還是下一代細胞治療最貴的門票？。https://drugnews.com.tw/articles/2026-05-03-in-vivo-cart-kelonia-lilly.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{"en":"2026-05-03-in-vivo-cart-kelonia-lilly-en.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}